Alembic announces USFDA Final Approval for Carbamazepine Tablets USP, 200 mg
Carbamazepine Tablets USP, 200 mg have an estimated market size of US$ 32 million for twelve months ending December 2024 according to IQVIA
Carbamazepine Tablets USP, 200 mg have an estimated market size of US$ 32 million for twelve months ending December 2024 according to IQVIA
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
The product will be launched in Q1FY26
The supply of these goods is set to commence within the first quarter of FY26
Pregabalin Gel 8% is a novel topical solution for diabetic neuropathic pain
Pantoprazole Sodium for Injection, 40 mg/vial (Single-Dose Vial) have an estimated market size of US$ 48 million for twelve months ending December 2024 according to IQVIA
Being a premium partner for pharmaceutical companies by contributing to safety and productivity of pharmaceutical manufacture
He has global experience in strategic and operational leadership levels with an extensive track record of leadership and success in building companies, businesses, teams, and brands for over 30 years
PRX-PLUS has a unique product feature with its deep-impacting formula
AstraZeneca Pharma India discontinues manufacturing of Imdur
Subscribe To Our Newsletter & Stay Updated